We are live on ! Find out more
ATXI

Avenue Therapeutics, Inc. Common Stock
ATXI

Delisted

ATXI was delisted on the 18th of March, 2025.

Back to rankings

13 hedge funds and large institutions have $15.1M invested in Avenue Therapeutics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

74% more capital invested

Capital invested by funds: $8.66M → $15.1M (+$6.41M)

7% less funds holding

Funds holding: 14 → 13 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Holders
13
Holders Change
-1
Holders Change %
-7.14%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
5
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
+$510K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$189K
3
AWS
AJ Wealth Strategies
New York
+$119K
4
6CM
683 Capital Management
New York
+$83.9K
5
Renaissance Technologies
Renaissance Technologies
New York
+$76.9K

Top Sellers

Rank Fund Capital Flow
1
EI
EAM Investors
California
-$126K
2
SIM
Spark Investment Management
New York
-$87K
3
Squarepoint
Squarepoint
New York
-$76K
4
UBS Group
UBS Group
Switzerland
-$14K
5
Victory Capital Management
Victory Capital Management
Texas
-$8K
Name Holding Trade Value Shares
Change 		Change in
Stake
OM
1
Opaleye Management
Massachusetts
$9.94M +$510K +73 +9%
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.61M +$189K +27 +22%
EI
3
EAM Investors
California
$887K -$126K -18 -18%
BRWA
4
B. Riley Wealth Advisors
Florida
$732K +$14K +2 +3%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$651K – – –
BlackRock
6
BlackRock
New York
$418K +$28K +4 +11%
FWM
7
Frontier Wealth Management
Missouri
$192K – – –
AWS
8
AJ Wealth Strategies
New York
$189K +$119K +17 New
Northern Trust
9
Northern Trust
Illinois
$140K – – –
6CM
10
683 Capital Management
New York
$131K +$83.9K +12 New
Renaissance Technologies
11
Renaissance Technologies
New York
$121K +$76.9K +11 New
Morgan Stanley
12
Morgan Stanley
New York
$31K +$14K +2 +200%
UBS Group
13
UBS Group
Switzerland
$19K -$14K -2 -50%
Royal Bank of Canada
14
Royal Bank of Canada
Ontario, Canada
$1K – – –
SIM
15
Spark Investment Management
New York
– -$87K -13 Closed
Squarepoint
16
Squarepoint
New York
– -$76K -11 Closed
Deutsche Bank
17
Deutsche Bank
Germany
– -$6.99K -1 Closed
Victory Capital Management
18
Victory Capital Management
Texas
– -$8K -1 Closed

ATXI Hedge Fund Activity: Q4 2019 in Review

13 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q4 2019, worth a combined $15.1M — up 74% from $8.66M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of ATXI and 3 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 5 added.

The largest buyer was Opaleye Management, adding an estimated $510K. The largest seller was EAM Investors, cutting an estimated $126K.

  • 13 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q4 2019, down from 14 in Q3 2019.
  • Funds reported $15.1M of Avenue Therapeutics, Inc. Common Stock stock for Q4 2019, up 74% quarter-over-quarter.
  • 3 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q4 2019 and 4 closed out, a net change of -1 holder.
  • The largest Avenue Therapeutics, Inc. Common Stock buyer in Q4 2019 was Opaleye Management, an estimated $510K added.
  • The largest Avenue Therapeutics, Inc. Common Stock seller in Q4 2019 was EAM Investors, an estimated $126K sold.

Based on aggregated 13F filings for Q4 2019.